Molecular antigen array

a technology of molecular antigen and array, which is applied in the field of molecular biology, virology, immunology and medicine, can solve the problems of not being able the risk of serious complications of a reversion to virulence and infection by the ‘vaccine’ organism, and the inability to carry out the antigen array, etc., and achieves high efficiency.

Inactive Publication Date: 2006-10-05
CYTOS BIOTECHNOLOGY AG
View PDF3 Cites 158 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0022] The invention provides a versatile new technology that allows production of particles or pili coated with any desired antigen. The technology allows the creation of highly efficient vaccines against infectious diseases and for the creation of vaccines for the treatment of allergies and cancers. The invention also provides compositions suited for the induction of Th type 2 T-helper cells (Th2 cells).

Problems solved by technology

Although a number of live attenuated viruses (e.g., measles, mumps, rubella, varicella, adenovirus, polio, influenza) and bacteria (e.g., bacille Calmette-Guerin (BCG) against tuberculosis) are successfully administered for vaccination, there is a risk for the development of serious complications related to a reversion to virulence and infection by the ‘vaccine’ organism, in particular in immunocompromised individuals.
However, the progression of acquired immunodeficiency syndrome (AIDS)-like symptoms in animals administered attenuated SIV raises safety concerns (Baba et al., Science 267: 1820-1825 (1995)).
One disadvantage of this vaccination strategy is that it does not mimic the virion surface, because the recombinant protein is expressed on the surface of the host cell.
Additionally, complications may develop in immunocompromised individuals, as evidenced by life-threatening disseminated vaccinia infections (Redfield, N. Eng. J. Med.
However, one significant problem with this approach is that it provides a limited immune response to the protein as a whole.
However, this distinction may turn out to be a disadvantage for the application of bacterial antigens, since non-native post-translational modification may result in reduced immunogenicity.
In addition, viral surface proteins are not highly organized in the absence of matrix proteins.
However, no constant relationship exists between IgG titers and symptom relief Presently, this is an extremely time- and cost-consuming process, to be considered only for patients with severe symptoms over an extended period each year.
It is well established that the administration of purified proteins alone is usually not sufficient to elicit a strong immune response; isolated antigen generally must be given together with helper substances called adjuvants.
However, a disadvantage of these viral mimicry systems is that they are not able to recreate the ordered presentation of antigen found on the viral surface.
However, this system is limited to very small peptides (5 or 6 amino acid residues) when the fusion protein is expressed at a high level (Iannolo et al., J.
Problems with the recombinant virus systems described so far include a low density expression of the heterologous protein on the viral surface and / or the difficulty of successfully and repeatedly creating a new and different recombinant viruses for different applications.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular antigen array
  • Molecular antigen array
  • Molecular antigen array

Examples

Experimental program
Comparison scheme
Effect test

example 1

Insertion of the JUN Amphiphatic Helix Domain Within E2

[0266] In the vector pTE5′2J (Hahn et al., Proc. Natl. Acad. Sci. USA 89: 2679-2683, (1992)), MluI and a BstEII restriction enzyme sites were introduced between codons 71 (Gln) and 74 (Thr) of the structural protein E2 coding sequence, resulting in vector pTE5′2JBM. Introduction of these restriction enzymes sites was done by PCR using the following oligonucleotides:

Oligo 1:E2insBstEII / BssHII:(SEQ. ID NO: 1)5′-ggggACGCGTGCAGCAggtaaccaccgTTAAAGAAGGCACC-3′Oligo 2:E2insMluIStuI:(SEQ ID NO: 2)5′-cggtggttaccTGCTGCACGCGTTGCTTAAGCGACATGTAGCGG-3′Oligo 3:E2insStuI:(SEQ ID NO: 3)5′-CCATGAGGCCTACGATACCC-3′Oligo4:E2insBssHII:(SEQ ID NO: 4)5′-GGCACTCACGGCGCGCTTTACAGGC-3′

[0267] For the PCR reaction, 100 pmol of each oligo was used with 5 ng of the template DNA in a 100 μl reaction mixture containing 4 units of Taq or Pwo polymerase, 0.1 mM dNTPs and 1.5 mM MgSO4. All DNA concentrations were determined photometrically using the GeneQuant app...

example 2

Production of Viral Particles Containing E2-JUN Using the pCYTts System

[0274] The structural proteins were PCR amplified using pTE5′2J: E2JUN as template and the oligonucleotides XbalStruct (ctatcaTCTAGAATGAATAGAGGATTCTTTAAC (SEQ ID NO:12)) and StructBsp1201 (tcgaatGGGCCCTCATCTTCGTGTGCTAGTCAG (SEQ ID NO:87)). For the PCR 100 pmol of each loligo was used and 5 ng of the template DNA was used in the 100 μl reaction mixture, containing 4 units of Tac or Pwo polymerase, 0.1 mM dNTPs and 1.5 mM MgSO4. All DNA concentrations were determined photometrically using the GeneQuant apparatus (Pharmacia). The polymerase was added directly before starting the PCR reaction (starting point was 95° C.). The temperature cycles were as follows: 95° C. for 3 minutes, followed by 5 cycles of 92° C. (30 seconds), 54° C. (35 seconds), 72° C. (270 seconds) and followed by 25 cycles of 92° C. (30 seconds), 63° C. (35 seconds), 72° C. (270 seconds. The PCR product was gel purified and digested with the rest...

example 3

Production of Viral Particles Containing E2-JUN Using the pTE5′2JE2: JUN Vector

[0279] RNase-free vector (1.0 μg) was linerarized by PvuI digestion. Subsequently, in vitro transcription was carried out using an SP6 in vitro transcription kit (InvitroscripCAP by InvitroGen, Invitrogen BV, NV Leek, Netherlands). The resulting 5′-capped mRNA was analyzed on a reducing agarose-gel.

[0280] In vitro transcribed mRNA (5 μg) was electroporated into BHK 21 cells (ATCC: CCL10) according to Invitrogen's manual (Sindbis Expression system, Invitrogen BV, Netherlands). After 10 hours incubation at 37° C., the FCS containing medium was exchanged by HP-1 medium without FCS, followed by an additional incubation at 37° C. for 10 hours. The supernatant was harvested and analyzed by Western blot analysis for production of viral particles exactly as described in Example 2.

[0281] The obtained result was identical to the one obtained with pCYTtsE2: JUN as shown in FIG. 2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
optical densityaaaaaaaaaa
temperaturesaaaaaaaaaa
temperaturesaaaaaaaaaa
Login to view more

Abstract

The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a core particle that is coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority benefit of U.S. provisional application No. 60 / 202,341, filed May 5, 2000, which is incorporated by reference in its entirety.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to generate defined self-specific antibodies and specific immune responses of the Th2 type. [0004] 2. Background Art [0005] Vaccine development for the preventio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/40A61K39/295A61K39/29A61K39/108A61K38/00A61K39/385A61P31/00A61P35/00A61P37/00A61P37/08C07K14/245C12N15/30C12N15/31C12N15/33C12N15/51
CPCA61K38/00A61K39/385A61K2039/57Y10S530/807A61K2039/625C07K14/245C07K2319/00A61K2039/6068A61P31/00A61P35/00A61P37/00A61P37/08
Inventor SEBBEL, PETERDUNANT, NICOLASBACHMANN, MARTINTISSOT, ALAINLECHNER, FRANZISKARENNER, WOLFGANGHENNECKE, FRANKNIEBA, LARS
Owner CYTOS BIOTECHNOLOGY AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap